Compare Iris Energy Limited (IREN) vs Eli Lilly And Co (LLY) Price & Performance

IREN is trading at $35.71, down 7.7% in the last 24 hours, showing bearish technical momentum despite strong analyst support. The company reported $501M revenue in 2025 with 17.35% profit margin, but faces significant losses projected for 2026 (-$703M net income). Recent news highlights IREN's pivot from Bitcoin mining to AI infrastructure with major contracts including a $9.7B Microsoft deal, though execution risks and capital intensity remain concerns.

While Wall Street maintains bullish sentiment with an $81 consensus price target (80% buy ratings), IREN faces substantial execution risks amid aggressive expansion. The stock offers potential upside if the company successfully scales its AI infrastructure business, but current negative profitability and high valuation ratios (P/E 51.42, P/S 15.97) suggest caution for near-term investors.

Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.

LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.